Marlborough, MA, United States
Marlborough, MA, United States

Time filter

Source Type

Patent
Theracos | Date: 2013-09-30

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.


Patent
Theracos | Date: 2012-08-31

Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.


Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M_(1) antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M_(1) antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M_(1) antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M_(1) antagonist.


Patent
Theracos | Date: 2016-08-16

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.


Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.


Patent
Theracos | Date: 2014-10-10

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.


Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.


Patent
Theracos | Date: 2015-02-20

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.


Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M_(1 )antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M_(1 )antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M_(1 )antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M_(1 )antagonist.


Patent
Theracos | Date: 2011-06-13

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Loading Theracos collaborators
Loading Theracos collaborators